Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.37 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.37 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651958 | 0.84 | NAPRT (0.39) | NAPRTSMN1; SMN2LMNAGABRPGABRD | |
| SCHEMBL18054000 | 0.84 | SIRT6 (0.43) | LMNAALDH1A1SIRT6ERN1KMT2A | |
| SCHEMBL29775020 | 0.80 | KDM4E (0.40) | SMN1; SMN2LMNAALDH1A1POLBERN1 | |
| SCHEMBL1553383 | 0.80 | ALDH1A1 (0.38) | ALDH1A1ERN1HPGDKMT2A | |
| SCHEMBL29773884 | 0.78 | NAPRT (0.47) | NAPRTSMN1; SMN2LMNAGABRPGABRD | |
| SCHEMBL979398 | 0.78 | NAPRT (0.47) | NAPRTSMN1; SMN2LMNAGABRPGABRD | |
| SCHEMBL29446081 | 0.76 | SMN1; SMN2 (0.47) | NAPRTSMN1; SMN2LMNAGABRPGABRD | |
| SCHEMBL29186263 | 0.76 | NAPRT (0.45) | NAPRTSMN1; SMN2LMNAGABRPGABRD | |
| SCHEMBL625580 | 0.76 | SMN1; SMN2 (0.47) | NAPRTSMN1; SMN2LMNAGABRPGABRD | |
| SCHEMBL903465 | 0.76 | PKM (0.37) | SMN1; SMN2LMNAALDH1A1POLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034134-A1 | 15-PGDH INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-01-30 | — | — | US | disclosed |
| EP-4434986-A1 | 15-PGDH INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2024-09-25 | — | — | EP | disclosed |
| US-20240279218-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2024-08-22 | — | — | US | disclosed |
| CN-117285525-A | Novel isoxazolyl ether derivatives as GABAA alpha 5PAM | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-109923113-B | Isoxazolyl ether derivatives as GABA A alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023088425-A1 | 15-PGDH INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023088425-A1 | 15-PGDH INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-05-25 | — | — | WO | disclosed |
| CN-116135856-A | 15-PGDH inhibitor and application thereof | 武汉人福创新药物研发中心有限公司 | 2023-05-19 | — | — | CN | disclosed |
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| EP-2102199-B1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | ASTRAZENECA AB (SE) | 2011-04-27 | — | — | EP | disclosed |
| US-7674801-B2 | Alkyl urea substituted pyridines | ASTRAZENECA AB (SE) | 2010-03-09 | — | — | US | disclosed |
| US-7674801-B2 | Alkyl urea substituted pyridines | ASTRAZENECA AB (SE) | 2010-03-09 | — | — | US | disclosed |
| US-7674801-B2 | Alkyl urea substituted pyridines | ASTRAZENECA AB (SE) | 2010-03-09 | — | — | US | disclosed |
| EP-2102199-A1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008068470-A1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008068470-A1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | WO | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB1, GABRA1 | NAPRT 3952/4885SMN1; SMN2 2580/4885LMNA 2024/4885 |
| US-20250034134-A1 | 15-PGDH INHIBITOR AND USE THEREOF | HPGD, UGDH, PGD | NAPRT 351/4885SMN1; SMN2 4706/4885LMNA 2476/4885 |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | MRPL21, NISCH, ABCB11 | NAPRT 1564/4885SMN1; SMN2 4319/4885LMNA 3493/4885 |
| US-20240279218-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB1, GABRA1 | NAPRT 3952/4885SMN1; SMN2 2580/4885LMNA 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.